Search

Heron Therapeutics Inc

Lezárt

SzektorEgészségügy

0.32 -3.03

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

0.3

Maximum

0.33

Fő mutatók

By Trading Economics

Bevétel

2.6M

-5.5M

Értékesítés

3M

38M

Egy részvényre jutó nyereség

-0.03

Profit margin

-14.573

Munkavállalók

128

EBITDA

2.1M

-5.5M

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-33M

63M

Előző nyitás

3.35

Előző zárás

0.32

Hangulat hírek alapján

By Acuity

69%

31%

294 / 340 Rangsor szerint Healthcare

Heron Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 11. 23:56 UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

2026. aug. 11. 23:56 UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

2026. aug. 11. 23:56 UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

2026. aug. 11. 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

2026. aug. 11. 23:51 UTC

News

Matthews International Corp names Michael J. Whitehead as CEO, succeeding Joseph C. Bartolacci. Shares are trading higher in after-market hours amid leadership transition optimism.

2026. aug. 11. 23:46 UTC

News

Kilroy Realty Corp shares are higher in after-market trading following the departure of CFO Jeffrey Kuehling and the appointment of Eliott Trencher as interim CFO.

2026. aug. 11. 23:46 UTC

News

Whirlpool Corp reported Q2 earnings that missed revenue and adjusted EPS expectations. Shares were roughly flat in after-market trading following the results.

2026. aug. 11. 23:41 UTC

News

Clean Energy Fuels reported Q2 revenue of $106.4 million, exceeding expectations. The positive outlook for profitability growth boosted shares during after-market hours.

2026. aug. 11. 23:41 UTC

News
Correlated Moves

BlackRock is joining Nvidia's $500 billion AI infrastructure initiative, though concerns about funding sustainability have contributed to lower after-market trading for the firm.

2026. aug. 11. 23:41 UTC

News

Anterix shares fell in after-market trading despite a fiscal Q1 earnings beat, reporting net income of $240,000 and EPS of $0.01.

2026. aug. 11. 23:41 UTC

News
Social Media

H&R Block reported fiscal 2026 revenue of $3.95 billion, exceeding expectations, and raised its dividend by 10%, contributing to a significant after-market increase.

2026. aug. 11. 23:36 UTC

News

UBS upgraded Jabil Inc to Buy, maintaining a $430 price target. Shares are trading higher in after-market hours, supported by strong technical indicators.

2026. aug. 11. 23:31 UTC

News

Ameresco Inc shares rose in after-market trading following strong Q2 earnings, reporting $515.5 million in revenue and raising full-year adjusted EPS guidance to $1.25.

2026. aug. 11. 23:26 UTC

News
Social Media

Oracle Corp partners with Quantinuum to enhance cloud services with quantum computing. Shares are trading higher in after-market hours following the announcement.

2026. aug. 11. 23:11 UTC

News
Social Media

General Motors shares declined in after-market hours following the announcement of a $4.5 billion Supplier Inventory Financing Program and plans to sell its battery joint venture stake.

2026. aug. 11. 23:11 UTC

News
Social Media

Lumentum Holdings reported fiscal Q4 adjusted EPS of $3.23, exceeding estimates, and provided optimistic Q1 FY27 guidance, driving shares higher in after-market hours.

2026. aug. 11. 23:06 UTC

News

Uber Technologies Inc. sold its entire stake in Serve Robotics, raising investor concerns about its delivery strategy. Shares traded lower during after-market hours.

2026. aug. 11. 23:06 UTC

News

ATI Inc reported stronger second-quarter results, raising 2026 adjusted EBITDA guidance to $1.135 billion to $1.185 billion. Shares advanced in after-market hours.

2026. aug. 11. 23:06 UTC

News

KKR & Co Inc has invested in Crowe Advisory LLC, enhancing service capabilities. Shares are trading higher in after-market hours following the announcement.

2026. aug. 11. 23:06 UTC

News

SiTime Corp shares rose in after-market trading following a strong earnings report, highlighting 127% revenue growth and GAAP profitability.

2026. aug. 11. 23:06 UTC

News

Blue Owl Capital prices $750 million in Senior Notes due 2036, aiming to repay borrowings. Shares are higher in after-market trading following the announcement.

2026. aug. 11. 23:06 UTC

News

UBS initiated coverage on Century Aluminum Co with a Buy rating and a $60 price target, contributing to after-market gains.

2026. aug. 11. 23:02 UTC

News

Agree Realty Corp declared a monthly cash dividend of $0.267, a 4.3% increase, contributing to a modest rise in shares during after-market hours.

2026. aug. 11. 23:01 UTC

News

Siebert Financial Corp reports Q2 revenue of $31.2 million, up from $14.9 million last year. Shares are trading higher in after-market hours.

2026. aug. 11. 23:01 UTC

News

Century Communities has acquired the Harbor Pointe community in Santa Ana. Shares are lower during after-market hours despite this expansion in Southern California.

2026. aug. 11. 23:01 UTC

News

PagSeguro Digital shares rose in after-market hours following its Q2 earnings report, which showed a recurring net profit of 576 million reais, exceeding estimates.

2026. aug. 11. 23:01 UTC

News
Event

Astronics Corporation reported second-quarter net income of $35.1 million and raised full-year revenue guidance, boosting shares higher in after-market trading.

2026. aug. 11. 23:01 UTC

News

Arbor Realty Trust closed an $825 million collateralized loan obligation securitization, enhancing its balance sheet. Shares moved higher during after-market hours.

2026. aug. 11. 23:01 UTC

News

Stereotaxis reported second-quarter revenue of $7.67 million, missing estimates and down from last year's $8.90 million. Shares traded roughly flat in after-market hours.

2026. aug. 11. 23:01 UTC

News

Darling Ingredients announced a $150 million sale of production tax credits, boosting shares in after-market hours as investors react positively to the deal.

Társak összehasonlítása

Árváltozás

Heron Therapeutics Inc Előrejelzés

Értékelési konszenzus

By TipRanks

Semleges

2 ratings

0

Vétel

2

Tartás

0

Eladás

Hangulat

By Acuity

294 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat